Table 6 Outcomes across the EGDT, ProCESS, and ARISE trials
| Â | EGDT | ProCESS | ARISE | ProMISe | |||||
|---|---|---|---|---|---|---|---|---|---|
| Â | EGDT | Control | EGDT | PBST | UC | EGDT | UC | EGDT | UC |
APACHE II at enrollment | 21.4 ± 6.9 | 20.4 ± 7.4 | 20.8 ± 8.1 | 20.6 ± 7.4 | 20.7 ± 7.5 | 15.4 | 15.8 | 18.7 ± 7.1 | 18.0 ± 7.1 |
Predicted mortality, % based on APACHE II | 40.3 | 36.9 | 38.2 | 37.5 | 37.9 | 21.0 | 21.0 | 30.2 | 29.1 |
In-hospital mortality, % (actual) | 30.5 | 46.5 | 21.0 | 18.2 | 18.9 | 14.5 | 15.7 | 25.6 | 24.6 |
Predicted minus actual mortality, % | 9.8 | −9.6 | 17.2 | 19.3 | 19.0 | 6.5 | 5.3 | 4.6 | 4.5 |
Relative risk reduction in hospital mortality | 24.3 | −26.0 | 45.0 | 51.5 | 50.1 | 30.9 | 25.2 | 25.6 | 24.6 |
Incidence of cardiovascular complications % | 10 | 20 | 5.2 | 4.9 | 8.1 | 7.1 | 5.3 | 2.1 | 1.6 |